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ABSTRACT 
Corticobasal degeneration (CBD) is a neurodegenerative condition characterized by 4R-tau 
protein deposition in several brain regions that clinically manifests itself as a heterogeneous 
atypical parkinsonism typically expressing in the adulthood. The prototypical clinical 
phenotype of CBD is corticobasal syndrome (CBS). Important insights into the 
pathophysiological mechanisms underlying motor and higher cortical symptoms in CBS have 
been gained by using advanced neuroimaging and neurophysiological techniques. Structural 
and functional neuroimaging studies often showed asymmetric cortical and subcortical 
abnormalities, mainly involving perirolandic and parietal regions and basal ganglia structures. 
Neurophysiological investigations including electroencephalography and somatosensory 
evoked potentials provided useful information on the origin of myoclonus and on cortical 
sensory loss. Transcranial magnetic stimulation demonstrated heterogeneous and asymmetric 
changes in the excitability and plasticity of primary motor cortex and abnormal hemispheric 
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connectivity. Neuroimaging and neurophysiological abnormalities in multiple brain areas 
reflect the asymmetric neurodegeneration, leading to the asymmetric motor and higher 
cortical symptoms in CBS. 
  
INTRODUCTION 
Corticobasal degeneration (CBD) is considered a rare progressive neurodegenerative disorder 
with onset in the adulthood, with a fatal prognosis and no effective therapies 1-3]. CBD is 
characterized by 4R tau protein deposition in the microtubule-binding domain and, in a 
minority of patients, by deposition of the microtubule associated protein tau (MAPT) 
haplotype H1 subtype c 4-7]. Four-R tau protein pathology is also found in other 
neurodegenerative disorders such as progressive supranuclear palsy (PSP). CBD and PSP, 
however, differ in histopathological findings and topographic tau-deposition distribution 7, 
8]. Whether CBD and PSP should be considered two different phenotypes of the same 
disorder remains a matter of debate owing to the significant overlap in the clinical features of 
CBD and PSP 9-11]. 
Clinically, the prototypical phenotype of CBD is corticobasal syndrome (CBS), which 
is found in 35-50% of patients with pathologically confirmed CBD 1, 3]. CBS is 
characterized by parkinsonism and a combination of asymmetric motor (rigidity, akinesia, 
dystonia and myoclonus) and higher cortical symptoms mainly of the cognitive-behavioral 
domain (apraxia, agnosia, cortical sensory loss and alien limb phenomena). Besides CBS, 
CBD may manifest with other clinical phenotypes such as the frontal behavioral-spatial 
syndrome (FBS) and the non-fluent/agrammatic variant of primary progressive aphasia 
(naPPA). Furthermore, CBS may also be the clinical manifestation of other tauopathies, such 
as PSP, frontotemporal lobar degeneration (FTLD) with parkinsonism linked to chromosome 
17, Alzheimer’s disease (AD) and posterior cortical atrophy (PCA) 1-3]. The high rate of 
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clinical overlapping between these neurodegenerative disorders make the in vivo diagnosis of 
CBD rather challenging. The specific clinical features manifested by the patients with CBS 
reflect however, the distribution of the underlying tau-related pathology. Clinico-pathological 
studies indeed suggested that CBS reflects neurodegenerative processes characterized by 
prominent perirolandic atrophy 12, 13]. 
 Although a number of advances have been made in the definition of the clinical and 
pathological features of this neurodegenerative condition over the last decade, the 
pathophysiological mechanisms underlying the motor and higher cortical abnormalities 
associated with this disease are still unclear. In this review, we report the most relevant 
neuroimaging and neurophysiological studies performed in patients affected by CBS 
discussing the most recent advances in the pathophysiology of CBS. 
 
Literature Search and methods 
A literature search was performed using the electronic databases PubMed, Scopus, Cochrane 
Library and Web of Science using the following key-words: “corticobasal degeneration” or 
“corticobasal syndrome” and “neuroimaging” or “PET” or “SPECT” or “structural MRI” or 
“DTI” or “functional MRI” or “resting state MRI”. We also used as key-words “corticobasal 
degeneration” or “corticobasal syndrome” and “neurophysiology” or “transcranial magnetic 
stimulation” or “movement analysis”. In this paper, we have reviewed and discussed   
neuroimaging and neurophysiological studies which gave the most informative contribution 
to the issue of pathophysiology of CBS. It is important to note that in the large majority of the 
studies there was no pathological confirmation of the diagnosis of CBD. Moreover, since 
validated and uniformly employed diagnostic criteria have been achieved only over recent 
years 1, 3], the studies performed before 2013 are characterized by a less rigorous 
terminology (i.e. indiscriminately using terms like CBD and CBS). Accordingly, in this 
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review, we will use the term CBS instead of CBD for all neuroimaging and 
neurophysiological studies not including post mortem diagnosis of CBD.  
 
NEUROIMAGING STUDIES  
During the early 1990s, neuroimaging studies in patients diagnosed with CBS mainly focused 
on the evidence of asymmetric cerebral glucose hypometabolism and hypoperfusion in the 
fronto-parietal brain regions, basal ganglia and thalamus detected by means of  positron 
emission tomography (PET) and single photon emission computed tomography (SPECT) 
techniques 14-17]. More recently, PET and SPECT studies have confirmed that the 
distribution pattern of decreased glucose metabolism and cerebral blood flow in patients with 
CBS is asymmetric, with the fronto-parietal cortex and the subcortical structures, such as the 
caudate and putamen, contralateral to the clinically more affected side being involved to a 
greater extent 18-21]. Among SPECT techniques, dopamine (DA)-related ligands may be 
used to assess function at presynaptic (e.g. by means of DA transporter - DAT imaging) as 
well as postsynaptic binding sites (e.g. by means of D2 receptor imaging) in Parkinson’s 
disease (PD) as well as in atypical parkinsonism including PSP and CBS 22]. Several studies 
in CBS have demonstrated asymmetric reduction of dopaminergic function in caudate and 
putamen and an high degree of variability [22, 23-26]. Furthermore, in CBS the presynaptic 
nigrostriatal function may be preserved in the early stages in neuropathologically confirmed 
cases [25, 27, 28], suggesting a decrease in DAT activity developing in the late stages of 
disease [29]. Similarly, studies using D2 receptor SPECT analysis in CBS showed a variable 
asymmetric reduction of striatal D2 receptor binding accounting for the lack of response to 
dopaminergic therapy to motor symptoms in CBS [24, 25, 30, 31].  
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PET imaging with [11C] N-methylpiperidin-4-yl acetate, aimed to measure brain 
acetylcholinesterase activity, demonstrated altered cholinergic transmission in patients with 
CBS in the paracentral region, frontal, parietal and occipital cortices 32]. Recent [F-18]-AV-
1451 PET studies in patients with CBD, demonstrated asymmetric increased binding in 
several brain regions contralateral to the symptomatic body side 33-36]. Another PET study 
using 18-F-THK5351 reported increased binding retention in brain regions contralateral to 
the most affected limb 37]. All these reports however, are based on a limited number of CBS 
patients and not always with a pathological confirmation. Furthermore the limitation of these 
PET studies is due to the rather limited binding of the tau ligand to straight filament 4R 
predominant tau and the off-target binding 38].  
Neuroimaging approaches have recently provided new tools to understand the 
pathophysiological changes underlying CBS through the detection of specific structural and 
functional biomarkers (Figure 1 and Table 1). Only few and dated studies with conventional 
MRI techniques have been conducted on CBS patients often reporting asymmetric fronto-
parietal cortical atrophy contralateral to the more clinically affected side 39-43]. By using 
voxel-based morphometry (VBM) approaches, some magnetic resonance imaging (MRI) 
studies, have revealed that CBS is associated with prominent asymmetric atrophy in the 
fronto-parietal cortex and in the basal ganglia 44-49]. In a previous study by Whitwell et al. 
47], CBS patients with a post-mortem diagnosis of CBD displayed focal atrophy of premotor 
and supplemental motor areas, while CBS patients with a post-mortem diagnosis of FTLD 
with TDP-43 immunoreactivity had widespread atrophy in the fronto-temporal lobe; CBS 
patients with a post-mortem diagnosis of AD showed atrophy in the temporo-parietal cortex 
and precuneus. In this study, all the CBS pathologic groups showed an asymmetric imaging 
pattern regardless the different brain areas involved 47]. Moreover, Burrell et al. (2014) 50] 
and Jütten et al. (2014) 51] reported an asymmetric fronto-parietal atrophy contralateral to 
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the apraxic limb suggesting unbalanced involvement of cortical atrophy in the 
pathophysiology of higher cortical symptoms. When Upadhyay et al. (2016) 52] more 
recently used surface-based morphometry (SBM) in patients with probable-CBS, they 
reported that reduced cortical thickness (CTh) in the fronto-parietal regions contralateral to 
the clinically more affected side is a more sensitive measure than volumetric changes. Hence, 
the distribution of neurodegenerative cortical processes appears to be directly related to the 
pathophysiology of the asymmetric presentation of motor and higher cortical symptoms in 
CBS 52]. Furthermore, asymmetric SBM changes in patients with probable-CBS have been 
reported to decrease as the disease progresses, which suggest that, the neurodegenerative 
process spreads bilaterally, involving both hemispheres in the advanced stages of the disorder 
52]. The complex clinical phenotype observed in the advanced stages of CBS is likely to 
result from a more widespread pattern of cortical and subcortical areas degeneration. SBM 
studies have shown that patterns of structural changes in patients with CBS differ from those 
in patients with PSP. CTh in the peri-rolandic regions was smaller in CBS than in PSP 
patients, while surface area (SA) was markedly smaller in PSP suggesting a greater intra-
cortical WM loss in this condition than in CBS 53]. Overall, these SBM findings point to 
different pathophysiological mechanisms in PSP and CBS, which is in keeping with 
pathological evidence of greater tau protein deposition in subcortical structures, including the 
brainstem and cerebellum, in PSP patients than in CBD patients 53]. 
Diffusion tensor imaging (DTI) studies on patients with CBS have revealed WM 
abnormalities in associative fiber bundles and in the cortico-spinal tract 54-56], in addition 
to asymmetric abnormalities of the corpus callosum, premotor and prefrontal white matter 
57]. These findings point to intra and inter-hemispheric structural disconnection processes 
possibly contributing to the pathophysiology of motor and higher cortical symptoms in CBS 
patients. More recently, Upadhyay et al. (2016) found axial diffusivity (AxD) to be more 
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affected than radial diffusivity changes (RD) in probable-CBS patients 52, 53]. Giving that, 
among DTI measures, AxD points to axonal loss, whereas RD changes denotes myelin 
damage, the authors concluded that WM changes in CBS patients reflect prominent axonal 
damage rather than demyelination 52, 53]. A recent longitudinal study reported DTI changes 
around the central sulci and in the superior fronto-occipital fasciculus over a 6 month follow-
up period suggesting that DTI measures might help to follow the pathological progression in 
patients with CBS 56]. Further noteworthy information has come from DTI studies 
comparing patients with CBS and PSP. Whitwell et al. (2014) 56] showed that patients with 
CBS had a more supratentorial, posterior and asymmetric pattern of DTI abnormalities with 
greater involvement of the splenium of the corpus callosum, premotor, motor and parietal 
lobes than patients with PSP. Conversely, PSP showed a more symmetric and infratentorial 
pattern of degeneration, with greater involvement of the superior cerebellar peduncles and 
midbrain than CBS 56]. Upadhyay et al. (2016) 53] found marked alterations in AxD in 
CBS, suggesting a prominent axonal loss, as opposed to increased RD and unaltered AxD in 
patients with PSP suggesting greater degree of myelin than axonal damage. 
Besides structural MRI findings, several authors have investigated possible functional 
connectivity (FC) changes in patients with CBS using resting-state functional MRI (rs-fMRI) 
58-60]. Bharti et al. (2017) 59] showed that patients with CBS had increased within-
network FC than healthy subjects in the default mode, cerebellum, sensorimotor, executive-
control and insular networks suggesting global intrinsic hyperconnectivity among brain 
regions deputed to motor and cognitive/affective functions. Increased FC has been interpreted 
as a plasticity-related shift in neuronal activity from atrophic to intact brain structures or as a 
direct consequence of disrupted neuronal activity caused by neurodegeneration 59]. 
Upadhyay et al. (2017) 60] found an increased FC between the dentate nucleus and the 
sensorimotor cortices, mainly contralateral to the most clinically affected body side, 
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suggesting an unbalanced reorganization of the cerebellum connections secondary to 
asymmetric motor and higher cortical symptoms. Again Ukmar et al. 58] reported the 
reduced activation of the motor areas and parietal lobe contralateral to the more affected arm 
during a simple and complex motor task. Furthermore, fMRI studies have disclosed marked 
differences in FC between patients with CBS and those with PSP. Functional disconnection 
of the thalamus with various cortical and cerebellar areas was evident in both syndromes, 
while FC of the dentate nucleus decreased in subcortical and prefrontal cortical areas in PSP, 
but increased asymmetrically in the frontal cortex in CBS 59, 60]. 
To sum up, molecular and structural neuroimaging studies have suggested the 
pathophysiological role in patients with CBS for asymmetric abnormalities in the premotor, 
motor and parietal cortical areas in addition to neurodegeneration in subcortical structures 
including basal ganglia and corpus callosum. As the disease progresses, multiple brain areas 
are involved and both hemispheres are affected in the late stages of CBS. Furthermore, 
functional neuroimaging studies have proved a functional involvement of multiple inter and 
intra-hemispheric brain connections including cerebellum, sensory-motor and insular 
networks.  
 
NEUROPHYSIOLOGICAL STUDIES  
Observations from neurophysiological studies on patients with CBS are prevalently based on 
a limited number of participants. As shown in Figure 2 and Table 2, the majority of 
neurophysiological studies on CBS patients have been designed to explore single motor (e.g. 
myoclonus) or higher cortical symptoms (e.g. apraxia) and have rarely adopted standardized 
clinical criteria for the diagnosis of CBS. Early neurophysiological studies on CBS suggested 
that apraxia might reflect the altered integration of somatosensory afferent inputs in the 
fronto-parietal cortices, which would in turn lead to cortical sensory loss or alien limb 
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phenomena, two higher cortical symptoms observed in CBS 61-66]. Leiguarda et al. 67] 
analyzed the kinematic features of apraxic movements reporting delayed initiation of the 
movement and slowed, distorted and fragmented finger movements of the affected hand. 
Furthermore, Okuda et al. (1998) 68] hypothesized that the prolonged somatosensory evoked 
potential (SEP)’ N20 component latency plays a role in the pathophysiology of cortical 
sensory loss and apraxia. Another typical symptom in CBS is myoclonus, which is usually 
characterized by a pattern of a synchronous, short-lasting EMG bursts recorded from agonist 
and antagonist muscles. CBS may also manifest itself through action myoclonus usually 
associated with a dystonic posture 69, 70]. These neurophysiological patterns of myoclonus 
observed in CBS appear to be different from those observed in other complex syndromes 
associated with parkinsonism, such as multiple system atrophy 69, 70]. Furthermore, the 
lack of associated large EEG potentials or giant SEPs and the shorter latency of myoclonus in 
CBS than that observed in the classical stimulus-sensitive myoclonus lend further support to 
the existence of a subcortical network underlying myoclonus in CBS 69, 70]. 
The neurophysiological tools currently available include transcranial magnetic 
stimulation (TMS), which has been increasingly used to investigate the primary motor cortex 
(M1) excitability and functional connectivity between brain areas 72,73]. Previous TMS 
studies on CBS reported an increased resting motor threshold (RMT) and flattened 
input/output (I/O) curve, thus pointing to a reduced M1 excitability in this disorder 73]. The 
observation that the cortical silent period (cSP) is also shortened in patients with CBS is 
indicative of a deficit in GABA-ergic inhibition in M1. In addition, by using single-pulse 
TMS to elicit the ipsilateral silent period (iSP), which reflects the activation of inter-
hemispheric connections, Trompetto et al. (2003) 65] found a reduced iSP suggesting 
reduced transcallosal inhibition in CBS. Paired-pulse TMS protocols revealed reduced short-
interval intracortical inhibition (SICI) in patients with CBS, which again demonstrates 
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reduced GABA-ergic inhibition in M1 61-64, 66]. Interestingly, there was a significant 
correlation between the amount of SICI and the degree of M1 atrophy as measured by VBM, 
which points to a pathophysiological role of M1 atrophy in the genesis of motor and higher 
cortical symptoms in CBS 74].  
More advanced repetitive TMS techniques, such as theta-burst stimulation (TBS), 
have more recently been used to study mechanisms of synaptic plasticity in M1 in patients 
with CBS 75-78]. In humans, synaptic plasticity can be assessed in M1 by measuring long-
term changes in motor evoked potentials (MEPs) amplitude following repetitive stimulation 
of M1 with plasticity-inducing protocols. In particular, intermittent-TBS elicits mechanisms 
of long-term potentiation (LTP)-like plasticity, whereas continuous-TBS induces mechanisms 
of long-term depression (LTD)-like plasticity 75-78]. LTP and LTD-like plasticity are 
physiological mechanisms that have been widely acknowledged to underlie motor execution 
and learning. Investigating M1 plasticity is an issue of considerable scientific relevance to 
better interpret the pathophysiology of motor symptoms in neurodegenerative disorders 
including CBS 75-79].   
In a relatively large cohort of patients with probable-CBS, TBS disclosed 
heterogeneous features 76]. In one subgroup of these patients, MEPs were virtually un-
recordable and typically polyphasic in shape, even at the maximum stimulator output. This 
suggests that the cortico-spinal tract is involved in widespread cortical degeneration, which 
may be a consequence of a more advanced disease and lead to a de-efferentation process 74, 
76, 80]. The study also revealed asymmetric responses in terms of LTP- and LTD-like 
plasticity when the M1 contralateral to the clinically less affected side (manifesting 
parkinsonism) was compared with that on the clinically more affected side (manifesting 
dystonia, apraxia, alien limb phenomena and cortical sensory deficit) 76]. This 
heterogeneous neurophysiological response to TBS seems to be specific to CBS and is in 
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contrast to the response reported in PSP, which is characterized by enhanced M1 LTP-like 
plasticity 76, 79, 81]. Within this context, the different responses to TBS-induced LTP/LTD-
like plasticity in patients with PSP and CBS suggest that the underlying pathophysiological 
mechanisms in these two conditions are different 76, 79].  
In summary, prolonged SEPs observed in CBS patients may reflect somatosensory 
cortex abnormalities causing apraxia and cortical sensory loss. Myoclonus in CBS is 
characterized by the absence of abnormal EEG potentials and giant SEPs and by a short onset 
latency suggesting the involvement of subcortical structures. MEPs after M1 stimulation in 
some patients are asymmetric or even absent implying an asymmetric impairment of the 
cortical-spinal tract. Furthermore, TMS studies have demonstrated altered M1 excitability, 
reduced intracortical and inter-hemispheric inhibition and abnormal integration of 
somatosensory afferent inputs in the motor and sensory cortices. The abnormal and often 
asymmetric M1 plasticity found in CBS patients also suggests abnormal motor inputs from 
non-primary motor and non-motor areas or from the basal ganglia.  
                                                           
DISCUSSION  
Recent neuroimaging studies demonstrated a number of structural, functional and metabolic 
abnormalities leading to a better understanding of pathophysiological mechanisms 
contributing to specific symptoms and signs in patients with CBS. Structural studies have 
demonstrated that asymmetric degeneration in fronto-parietal cortex is likely responsible for 
unilateral symptoms such as alien limb phenomena, cortical sensory loss and apraxia in CBS. 
Furthermore, neurodegeneration of subcortical brain areas, particularly the basal ganglia, and 
intra- and inter-hemispheric structural disconnection processes are likely to be involved in 
motor symptoms such as dystonia, myoclonus and parkinsonian features. Asymmetric DTI 
abnormalities in several associative fiber bundles and in the cortico-spinal tract may also 
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contribute to specific CBS features. As the disease progresses, additional cortical and 
subcortical brain areas become part of a wider neurodegenerative process that results in the 
heterogeneous and complex clinical phenotype that is typical of the late stage of CBS. In 
addition to structural abnormalities, SPECT and PET studies found asymmetric metabolic 
changes possibly contributing to parkinsonism and other asymmetric motor signs and 
symptoms in CBS. Asymmetric functional reorganization in cortical and sub-cortical 
structures likely plays an important role in the pathophysiology of CBS. Altered FC in 
cerebellum, thalamus, and sensorimotor cortex possibly reflects a global intrinsic hyper-
connectivity among brain networks compensatory to asymmetric motor and higher cortical 
symptoms. Recent neurophysiological studies have also led to a better understanding of the 
asymmetric neurophysiological abnormalities in specific brain networks in patients with CBS 
by shedding light on the correlation between altered neurophysiological mechanisms and 
asymmetric clinical symptoms. It is reasonable to assume that abnormal M1 excitability and 
LTP/LTD-like plasticity play a crucial role not only in rigidity and bradykinesia but also in 
focal motor symptoms such as dystonia, thereby reflecting the structural and functional 
impairment of cortico-basal ganglia-thalamo-cortical motor loops. By contrast, asymmetric 
higher cortical symptoms, such as apraxia, cortical sensory loss and alien limb phenomena, 
are likely to reflect a more complex neurophysiological model that results in a cortico-
cortical disconnection syndrome due to the altered integration of somatosensory afferent 
inputs in the motor and sensory cortices. Asymmetric neurophysiological measures might 
help in differentiating CBD/CBS from other clinical presentations of CBD (e.g. PSP-S) 82, 
83]. Hence, structural and functional neuroimaging and neurophysiological studies on CBS 
have clearly revealed a degree of asymmetry in a number of structural and functional 
measures that highlights the imbalance in the severity of the neurodegenerative processes in 
the two hemispheres. This imbalance in turn leads to the typical asymmetric CBS phenotype 
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characterized by prominent motor and higher cortical symptoms involving the limb 
contralateral to the more affected hemisphere. It is important to underline that although CBS 
diagnosis is supported by the presence of asymmetric clinical and neuroimaging features, a 
clinico-pathological study reported a post-mortem diagnosis of CBD in patients with 
symmetric clinical motor symptoms and symmetric structural and functional neuroimaging 
abnormalities 82]. 
 One important pathophysiological issue in CBS that has yet to be explained concerns 
the etiopathogenetic mechanisms underlying the asymmetric degeneration and, consequently, 
the asymmetric presentation of the motor and higher cortical symptoms. One clinical study on 
a small cohort of patients with CBS reported that arm dystonia, a common motor symptom of 
the CBS spectrum, is more often observed on the contralateral side of the dominant hand 
84]. Considering the disproportionate use of the dominant arm for a range motor tasks, it has 
been speculated that the non-dominant hemisphere may be more susceptible to 
neurodegenerative processes owing to a difference in the “strength” of the neuronal networks 
between that hemisphere and the dominant hemisphere 84]. Whether the asymmetric 
neuronal degeneration in CBD starts from an involvement of more vulnerable areas or not is 
however still unclear. One explanation might be that the asymmetry in macroscopic grey 
matter atrophy and white matter degeneration in CBD reflects the asymmetry in microscopic 
tau protein deposition. This hypothesis is supported by histopathological studies on patients 
with post-mortem diagnosis of CBD that have disclosed an asymmetric aggregation of tau 
protein, with a greater aggregation in the hemisphere contralateral to the more affected body 
side 85].  The pathophysiological mechanisms underlying asymmetric tau protein deposition 
in CBD are far from clear. Boluda et al. (2015) 86] suggested that different types of tau 
induce a wide spectrum of brain pathologies that point to new models of self-propagating tau 
protein transmission through different interconnected neuroanatomical pathways. Although 
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this hypothesis is supported by a presumed pathophysiological link between the abnormal 
post-transcriptional phosphorylation of tau-protein and a range of cortical and subcortical 
dissemination patterns in tauopathies 86], the enigmatic pattern of distribution of tau 
pathology in CBD warrants further studies.  
In conclusion, this review focuses on neuroimaging and neurophysiological findings 
in CBS highlighting the important advances that have recently been made in our 
understanding of this disease and that point to asymmetry as a relevant feature of CBS. 
Indeed, recent neuroimaging and neurophysiological studies have shed light on the 
pathophysiological bases of asymmetric motor and higher cortical symptoms in patients with 
CBS. However, it should be taken into account that neurodegenerative disorders other than 
CBD may manifest with asymmetric clinical as well as neuroimaging features (e.g. FTLD, 
PSP, AD and PCA) and that CBD may manifest with symmetric clinical and neuroimaging 
features 82]. Furthermore, it is important to clarify that in the absence of a pathological 
confirmation of CBD in the large majority of neuroimaging and neurophysiological studies 
here reported, the observed findings should be interpreted and referred to the clinical 
phenotype of CBS rather than CBD. Moreover, owing to the well-known clinical 
heterogeneity of CBS, future studies on larger cohorts of patients clustered in homogeneous 
phenotypes and with pathological confirmation of CBD are required to reduce the overall 
current variability of neuroimaging and neurophysiological measures. Further 
multidisciplinary studies designed to combine neuroimaging and neurophysiological 
techniques will help to improve the in vivo diagnosis of CBD, which is crucial to design 
targeted therapies aimed at slowing down the pathological progression of this disease 87].  
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FIGURE LEGENDS 
 
Figure 1. Main neuroimaging findings reported in corticobasal degeneration and corticobasal 
syndrome studies. MRI: magnetic resonance imaging; VBM: voxel-based morphometry; 
SBM: surface-based morphometry; DTI: diffusion tensor imaging; RS-FMRI: resting-state 
functional-MRI; PET: positron emission tomography; [18F]FDG-PET: [(18)F]6-
fluorodeoxyglucose-PET; CBF: cerebral blood flow; SPECT: single photon emission 
computed tomography; FP-CIT-SPECT: ioflupane-SPECT; WM: white matter; CTh: cortical 
thickness; AxD, axial diffusivity; RD: radial diffusivity. 
 
Figure 2. Main neurophysiological findings reported in corticobasal syndrome studies. SEPs: 
somatosensory evoked potentials; EMG: electromiography; MA: movement analysis; TMS: 
transcranial magnetic stimulation; rTMS: repetitive TMS; TBS: theta burst stimulation; M1: 
primary motor cortex; GABA: gamma-aminobutyric acid; SICI: short-interval intracortical 
inhibition; ICF: intracortical facilitation; LTD: long-term depression; LTP: long-term 
potentiation. 
 
TABLE LEGENDS 
Table 1. Neuroimaging studies in patients with corticobasal degeneration (CBD) and 
corticobasal syndrome (CBS). PET: positron emission tomography; [18F]FDG-PET:  
[(18)F]6-fluorodeoxyglucose-PET; SPECT: single-photon emission computed tomography;  
FP-CIT SPECT: ioflupane-SPECT; D2: dopamine receptor 2; IBZM: iodobenzamide; CBF: 
cerebral blood flow; MRI: magnetic resonance imaging; GM: gray matter; WM: white 
matter; VBM: voxel-based morphometry; DTI: diffusion tensor imaging; SBM: surface-
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based morphometry; CTh: cortical thickness; AxD: axial diffusivity; RD: radial diffusivity; 
Rs-fMRI: resting-state functional-MRI; FC: functional connectivity. 
 
Table 2. Neurophysiological studies in patients with corticobasal syndrome (CBS). SEPs: 
somatosensory evoked potentials; TMS: transcranial magnetic stimulation; RMT: resting 
motor threshold; iSP: ipsilateral silent period; cSP: cortical silent period; I/O: input/output; 
MEP: motor evoked potential; SICI: short-interval intracortical inhibition; ICF: intracortical 
facilitation; iTBS: intermittent theta burst stimulation; cTBS: continuous theta burst 
stimulation; LTP: long-term potentiation; LTD: long-term depression.  
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Reference 
Number of 
patients 
 Pathological 
diagnosis of 
CBD 
Technique  Main finding 
Niethammer et al., 
2014 
10 CBD No [18F]FDG-PET 
Bilateral, 
asymmetric metabolic reductions in 
frontal and parietal cortex, thalamus, and 
caudate nucleus contralateral to the more 
affected limb 
Turaga et al., 2013 17 CBS No [18F]FDG-PET 
Asymmetric focal hypometabolism in 
frontal, parietal, temporal lobes and 
basal ganglia 
Blin et al., 1992 5 CBS No [18F]FDG-PET 
Asymmetric metabolic reductions in the 
temporal and sensorimotor cortex and 
thalamus contralateral to the most 
affected limbs 
Eidelberg et al., 
1991 
5 CBD No [18F]FDG-PET 
Asymmetric reduction of metabolism in 
the frontal and parietal lobe and, 
thalamus 
Kaasinen et al., 
2013 
1 CBD Yes FP-CIT.SPECT 
Preserved presynaptic dopaminergic 
bindings 
Ceravolo et al., 2013 4 CBS No FP-CIT.SPECT 
Pathological presynaptic dopaminergic 
uptake performed 10-15 months apart 
from the baseline scan. 
Cilia et al., 2011 36 CBS No FP-CIT-SPECT 
Large variability in presynaptic 
dopaminergic bindings. No correlation 
between tracer uptake values and clinical 
features 
O'Sullivan et al., 
2008 
1 CBD Yes FP-CIT-SPECT 
Preserved presynaptic dopaminergic 
bindings 
Pirker et al., 2013 9 CBS 
Only in 2 
patients 
D2 receptor-SPECT-
(123)I-IBZM 
Preserved striatal D2 receptor binding 
but more asymmetric than in controls 
Frisoni et al., 1995 1 CBS No 
D2 receptor-SPECT-
(123)I-IBZM 
Reduced and asymmetric striatal D2 
receptor binding 
Klaffke et al., 2006 8 CBS No 
D2 receptor-SPECT-
(123)I-
IBZM/[18F]FDG 
Contralateral hypometabolism in cortical 
and subcortical areas. Decreased 
presynaptic dopamine transporter 
binding. Preserved D2 receptor 
Hammesfahr et al., 
2016 
23 CBS 
 
No 
FP-CIT-SPECT and D2 
receptor-SPECT-
(123)I-IBZM 
Asymmetric reduction in presynaptic 
dopaminergic binding. IBZM uptake did 
not show abnormalities 
Plotkin et al., 2005 9 CBS No 
FP-CIT-SPECT and D2 
receptor-SPECT-
(123)I-IBZM 
Reduction in presynaptic dopaminergic 
binding contralateral to the more 
affected side. Reduced D2 receptor in 
2/9 CBS patietns 
Abe et al., 2016 26 CBS No MRI and CBF-SPECT 
Left frontal and temporal atrophy in 
CBS with aphasia. The CBF in the left 
middle frontal gyrus differed between 
CBS patients with and without aphasia 
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Slawek et al., 2001 2 CBD No CBF-SPECT 
left fronto-parieto-temporal cortex and 
striatal hypoperfusion 
Markus et al., 1995 8 CBS No CBF-SPECT 
Hypoperfusion in the frontal and parietal 
cortex contralateral to the more affected 
arm 
Hirano et al., 2010 7 CBS No 
[11C] N-
methylpiperidin-4-yl 
acetate-PET 
Altered cholinergic transmission in the 
paracentral region, frontal, parietal and 
occipital cortices 
Nagasawa et al., 
1996 
6 CBS No 
[18F]FDG 
and[18F]dopa-PET 
Asymmetric reduction of glucose 
metabolism in frontal and parietal cortex 
and basal ganglia. Asymmetric reduction 
of [18F]dopa in basal ganglia 
Cho et al., 2017 6 CBS No 
[18F]-AV-1451-PET 
(tau) 
Asymmetric increase of 18F-AV-1451 
binding in the putamen, globus pallidus, 
and thalamus contralateral to the 
clinically more affected side 
Smith et al., 2017 8 CBS No 
[18F]-AV-1451-PET 
(tau) 
Increased signal in the motor cortex, 
corticospinal tract, and basal ganglia 
contralateral to the affected body side 
Josephs et al., 2016 1 CBD Yes 
[18F]-AV-1451-PET 
(tau) 
Increased signal in putamen, pallidum, 
thalamus, precentral cortex, rolandic 
operculum, supplemental motor area, 
and left Broca’s area 
McMillan et al., 
2016 
1 CBD Yes 
[18F]-AV-1451-PET 
(tau) 
Increased signal in substantia nigra, 
globus pallidus, midbrain, bilateral 
frontal, posterior temporal cortex 
Kikuchi et al., 2016 5 CBS 
Only in a single 
patient 
18F-THK5351 
Higher 18F-THK5351 retention in the 
frontal, parietal, and globus pallidus,  
contralaterally to the side associated 
with greater cortical dysfunction and 
parkinsonism. 
Josephs et al., 2004 6 CBD Yes MRI 
Fronto-parietal cortical and middle 
corpus callosum atrophy 
Solivieri et al., 1999 16 CBS No MRI 
Asymmetric fronto-parietal cortical 
atrophy 
Hauser et al., 1996 8 CBS No MRI 
Asymmetrical cortical atrophy 
contralateral to the more affected side 
Grisoli et al., 1995 10 CBS No MRI 
Asymmetric atrophy (posterior-frontal 
and parietal regions) contralateral to the 
more affected side 
Gröschel et al., 2004 18 CBS No MRI volumetric 
GM loss in mid-brain, parietal WM, 
brainstem, pons, temporal brain regions 
Yu et al., 2015 
165 CBS (meta-
analysis study) 
No MRI (VBM) 
Asymmetric gray matter atrophy in 
multiple cortical regions mainly 
involving the superior parietal lobe 
Burrell et al., 2014 17 CBS No MRI (VBM) 
10/17 patients with asymmetric atrophy 
of the primary motor and pre-
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motor cortices and thalamus. 
Apraxia correlates with pre-motor and 
parietal atrophy 
Jutten et al., 2014 
8 CBS (left vs 
right affected 
side)  
No MRI (VBM) 
Asymmetric primary motor areas 
atrophy in the hemisphere contralateral 
to the apraxic limb. Volumetric grey 
matter loss related to CBS pathology 
appears and progresses faster in l-CBS 
than in r-CBS 
Whitwell et al., 2010 7 CBD Yes MRI (VBM) 
Focal atrophy involving the premotor 
and supplemental motor area 
Josephs et al., 2008 21 CBD Yes MRI (VBM) 
Asymmetric frontoparietal grey and 
subcortical grey matter atrophy (visual 
assessment) 
Boxer et al., 2006 14 CBS No MRI (VBM) 
Asymmetric pattern of brain atrophy in 
premotor and parietal cortex, superior 
parietal lobules, and striatum 
Borroni et al., 2008 20 CBS Yes MRI (VBM) and DTI 
Limb apraxia correlates with parietal 
atrophy and with fractional anisotropy 
reductions in the parietofrontal 
associative fibers 
Upadhyay et al., 
2016a 
11 CBS No SBM and DTI 
Reduced CTh in the fronto-parietal 
regions contralateral to the clinically 
more affected side. AxD more affected 
than RD 
Upadhyay et al., 
2016b 
11 CBS No SBM and DTI 
Reduced CTh in peri-rolandic brain 
regions 
Zhang et al., 2016 25 CBS No DTI 
Anisotropy reduction around the central 
sulci, and diffusivity increase in the 
superior fronto-occipital fascicules 
Tovar-Moll et al., 
2014 
19 CBS No DTI 
Damage to the midbody of the corpus 
callosum and perirolandic corona radiata 
Whitwell et al., 2014 9 CBS No DTI 
Asymmetric degeneration of the 
splenium of the corpus callosum, 
premotor and prefrontal white matter 
lobes  
Upadhyay et al., 
2017 
11 CBS No Rs-fMRI 
Increased FC between the dentate 
nucleus and the sensorimotor cortices 
contralateral to the most clinically 
affected body side 
Bharti et al., 2017 11 CBS No Rs-fMRI 
Increased within-network FC in the 
cerebellum, sensorimotor, executive-
control and insular networks.  
Ukmar et al., 2003 7 CBS No Rs-fMRI 
Decreased activation of the parietal lobe 
contralateral to the more affected arm 
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Reference 
Number of 
patients 
 
Pathological 
diagnosis of 
CBD 
Technique Main Finding 
 
Okuda et al., 1998 
 
5 CBS No SEPs Prolonged N20 latencies (apraxic limb) 
 
Brunt et al., 1995 
 
2 CBS No SEPs 
Small N20-P25, No giant SEPs (limb with 
myoclonus) 
Leiguarda et al., 
2003 
5 CBS No 
movement 
analysis 
 
 
Delayed initiation, distorted and fragmented 
finger movements 
 
Pal et al., 2008 7 CBS No single pulse TMS 
Normal/incr. RMT, reduced iSP, normal 
cSP and I/O 
 
Kühn et al., 2004 
 
13 CBS No single pulse TMS 
Reduced RMT, MEP amplitude, I/O, cSP 
and iSP 
Trompetto et al., 
2003 
7 CBS No single pulse TMS Reduced iSP duration 
Leiguarda et al., 
2003 
5 CBS No single pulse TMS Reduced cSP (apraxic limb) 
Valls-Solé et al., 
2001 
10 CBS No single pulse TMS 
Increased RMT, reduced MEP amplitude 
and cSP 
Lu et al., 1998 2 CBS No single pulse TMS 
Increased RMT, reduced MEP amplitude 
and cSP 
Pal et al., 2008 7 CBS No paired pulse TMS 
Reduced SICI, normal ICF 
Kühn et al., 2004 13 CBS No paired pulse TMS 
Reduced SICI, normal ICF 
Okuma et al., 2000 4 CBS No paired pulse TMS 
Reduced SICI 
Hanajima et al., 
1996 
1 CBS No paired pulse TMS Reduced SICI 
Suppa et al., 2016a 17 CBS No iTBS/cTBS 
 
Reduced LTP/LTD-like plasticity 
(park.hemisphere) 
red. or incr. LTP/LTD-like plasticity 
(park.plus hemisphere) 
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